title: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
authors.forename: Sara
authors.initials: S
authors.lastname: Redaelli
authors.forename: Rocco
authors.initials: R
authors.lastname: Piazza
authors.forename: Roberta
authors.initials: R
authors.lastname: Rostagno
authors.forename: Vera
authors.initials: V
authors.lastname: Magistroni
authors.forename: Pietro
authors.initials: P
authors.lastname: Perini
authors.forename: Manuela
authors.initials: M
authors.lastname: Marega
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.forename: Frank
authors.initials: F
authors.lastname: Boschelli
mesh_terms: D000814:Aniline Compounds / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D016313:Genes, abl / Q000235:genetics*; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D009570:Nitriles / Q000627:therapeutic use*; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011804:Quinolines; D013844:Thiazoles; C471992:bosutinib; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib